CTS™ OpTmizer™ T 细胞扩增 SFM 培养基，瓶装
Invitrogen17万+抗体限时买二赠一，靶点广，灵活用！
CTS™ OpTmizer™ T 细胞扩增 SFM 培养基，瓶装
引用和文献 (7)
Gibco™

CTS™ OpTmizer™ T 细胞扩增 SFM 培养基，瓶装

GIBCO OpTmizer™ CTS™ T 细胞扩增 SFM 培养基针对人 T 淋巴细胞的生长和扩增而开发。OpTmizer™了解更多信息
Have Questions?
货号数量
A10485011 瓶
货号 A1048501
价格（CNY)
3,084.00
Each
添加至购物车
数量:
1 瓶
价格（CNY)
3,084.00
Each
添加至购物车
GIBCO OpTmizer™ CTS™ T 细胞扩增 SFM 培养基针对人 T 淋巴细胞的生长和扩增而开发。OpTmizer™ CTS™ T 细胞扩增培养基是完整的无血清且不含异种成分的 1X 培养基，由 OpTmizer™ T 细胞扩增基础培养基（1 L 瓶）和 OpTmizer™ T 细胞扩增添加剂（26 mL）组成，在使用前混合在一起。

•与被激活并培养的多克隆T细胞在传统加血清培养基相比，可以维持与其相似的表型和功能（如细胞因子分泌表达情况）
•支持 T 细胞扩增方面有一致的表现
•在静态培养中支持高密度 T 细胞培养（例如 >3x106 CD3+ T 细胞/mL）

借助 OpTmizer™ T 细胞培养 SFM 培养基，我们同时为基础和临床研究人员提供了一种新工具，以增强他们在人 T 细胞培养方面的成功率。其特别配方可使细胞获得优良的生长与活性，可获得更少变异、更一致的结果，以及使从研究到临床应用的转化更容易。

工作流程优势：
•使得血清的采购、储存、质检等工作极大减少，降低了可变性和费用
•T 细胞扩增更快，减少了细胞培养周期，提高了生产率
•完全的无血清且不含异种成分的培养基，考虑到从研究到临床应用的无缝过渡，并尽可能降低法规监管工作量。
规格
细胞类型T 细胞
培养环境CO2
内毒素水平极低
所含抗生素不含抗生素
无机盐钙、镁
产品线CTS、OpTmizer
产品类型细胞扩增无血清培养基 (SFM)
纯度或质量等级研究级
数量1 瓶
分类无血清, 无异种成分
培养类型悬浮液细胞培养
形式液体
血清水平无血清
无菌无菌
加有添加剂HEPES：, 酚红, 丙酮酸钠, 碳酸氢钠
不加添加剂无谷氨酰胺
Unit SizeEach
内容与储存
OpTmizer™ T 细胞扩增基础培养基（1 x 1000 mL 瓶装）：储存于 2–8°C。避光。

OpTmizer™ T 细胞扩增添加剂 (1 x 26 mL)：2–8°C 条件下避光储存。

常见问题解答 (FAQ)

What is CTS?

The Gibco Cell Therapy Systems (CTS) portfolio of cell and gene therapy products are GMP manufactured, safety tested, and backed by regulatory documentation to support your transition from discovery through clinical and commercial manufacturing. Through our CTS solutions, we are committed to helping customers streamline therapeutic development, minimize risk, and ease the burden on their quality systems. Learn more here.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Do I need to order additional components with the CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503)?

The CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503) kit comes with OpTmizer T Cell Expansion Basal Medium and OpTmizer T Cell Expansion Supplement, which are mixed together prior to use. Depending on your protocol you may need to purchase T cell growth factors such as IL-2 (Cat. No. PHC0023) and L-glutamine (Cat. No. 25030) to form a complete medium. To boost growth of human T cells, human AB serum can be added. If desired, antibiotics such as Gentamicin (Cat. No. 15750), can also be added.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Will CTS OpTmizer T Cell Expansion SFM (Cat. No. A1048501, A1048502, A1048503) work with all types of T cells?

CTS OpTmizer T Cell Expansion SFM (Cat. No. A1048501, A1048502, A1048503) has been demonstrated to be effective for the ex vivo expansion of human CD3 T cells, including polyclonal T cell populations, antigen-specific T cells, tumor-infiltrating lymphocytes (TIL), cord blood T cells, regulatory T cells, T cells from HIV-infected donors, gene-modified T cells (both lenti- and MLV-based vectors), including cells of both the CD4+ and CD8+ phenotype.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Can CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503) be used for animal T cell cultures other than human?

CTS OpTmizer T Cell Expansion SFM (Cat. No. A1048501, A1048502, A1048503) has only been tested on human T cells.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Is there a difference in formulation of the CTS OpTmizer T Cell Expansion SFM between the bottle and bag packaging formats?

The bottle and bag packaging formats of the medium have the same formulation.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

View all CTS™ OpTmizer™ T 细胞扩增 SFM 培养基，瓶装 FAQs

引用和文献 (7)

引用和文献
Abstract
Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.
Authors:Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A,
Journal:Cancer Immunol Immunother
PubMed ID:19894047
'The choice of serum for supplementation of media for T cell assays and in particular, Elispot has been a major challenge for assay performance, standardization, optimization, and reproducibility. The Assay Working Group of the Cancer Vaccine Consortium (CVC-CRI) has recently identified the choice of serum to be the leading cause ... More
Impact of culture medium on the expansion of T cells for immunotherapy.
Authors:Sato K, Kondo M, Sakuta K, Hosoi A, Noji S, Sugiura M, Yoshida Y, Kakimi K,
Journal:Cytotherapy
PubMed ID:19903105
'BACKGROUND AIMS: Encouraging evidence of clinical benefits from cancer immunotherapy is beginning to accumulate in several clinical trials. Cancer immunotherapy is based on two main methods, active vaccination and cell-transfer therapy. The ex vivo expansion of T cells is required to monitor vaccine-induced antigen-specific T cells or prepare large numbers ... More
Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement.
Authors:Smith C, Økern G, Rehan S, Beagley L, Lee SK, Aarvak T, Schjetne KW, Khanna R
Journal:
PubMed ID:25671129
The manufacture of clinical grade cellular products for adoptive immunotherapy requires ex vivo culture and expansion of human T cells. One of the key components in manufacturing of T cell therapies is human serum (HS) or fetal bovine serum (FBS), which can potentially expose immunotherapy recipient to adventitious infectious pathogens ... More
Bioengineering and serum free expansion of blood-derived ?d T cells.
Authors:Sutton KS, Dasgupta A, McCarty D, Doering CB, Spencer HT
Journal:Cytotherapy
PubMed ID:27260209
'Cellular immunotherapy relies on several highly variable patient-specific parameters, such as (i) cell number before and after expansion, (ii) targeting of cells to tumors, (iii) cell survival and function after infusion, and (iv) on- and off-target adverse events. Cellular approaches such as the specific expansion of ?d T cells as ... More
A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies.
Authors:Lu TL, Pugach O, Somerville R, Rosenberg SA, Kochendefer JN, Better M, Feldman SA
Journal:Hum Gene Ther Methods
PubMed ID:27897048
The treatment of B-cell malignancies by adoptive cell transfer (ACT) of anti-CD19 chimeric antigen receptor T cells (CD19 CAR-T) has proven to be a highly successful therapeutic modality in several clinical trials.(1-6) The anti-CD19 CAR-T cell production method used to support initial trials relied on numerous manual, open process steps, ... More
View all CTS™ OpTmizer™ T 细胞扩增 SFM 培养基，瓶装 citations